Company: LCTX
Filing Date: 2025-07-02
Form Type: 8-K
Source: 0000950170-25-093007
Chunk: 1

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-07-02
Form: 8-K
Item: Item 5.07
Chunk 1
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting was held on June 26, 2025 and involved the election of directors of the Company and three other matters voted upon by the Company’s shareholders. The matters voted upon at the Annual Meeting are described in detail in the Proxy Statement. Below is a brief description of each such matter and the final voting results, including the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.

1.

Shareholders elected the seven nominees named below to the Board to hold office until the Company’s 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:

  Nominee                 Votes For      Votes Withheld      Broker Non-Votes  
 ───────────────────────────────────────────────────────────────────────────────
  Michael H. Mulroy      99,312,637           1,174,790            59,813,557  
  Dipti Amin             99,362,438           1,124,989            59,813,557  
  Deborah Andrews        98,593,393           1,894,034            59,813,557  
  Angus C. Russell       99,373,222           1,114,205            59,813,557  
  Neal C. Bradsher       98,861,237           1,626,190            59,813,557  
  Brian M. Culley        98,593,167           1,894,260            59,813,557  
  Anula Jayasuriya       99,077,018           1,410,409            59,813,557  

2.

Shareholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 by the following votes:

    Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ─────────────────────────────────────────────────────────────────────────
  158,952,692            912,282          436,010      —                 

3.

Shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers,